Related Experiment Video
Updated: Jun 7, 2025
Transvaginal Mesh Insertion in the Ovine Model
Published on: July 27, 2017
The Use of Reinforced Ovine Mesh in Implant Breast Reconstruction: Equivalent Outcomes to Human Acellular Dermal
Keith Sweitzer1, Raquel Arias-Camison, Carolyn Cafro
1From the Division of Plastic Surgery, Department of Surgery, University of Rochester, Rochester, NY.
Purpose:
The use of "mesh" in implant-based reconstruction is widespread, with both acellular dermal matrices (ADMs) and extracellular matrices (ECMs) being used, especially in prepectoral device placement. This study compared Ovitex (ovine ECM) versus human cadaveric ADMs to determine safety profiles and cost-effectiveness.
Methods:
A single surgeon's longitudinal experience with 2-stage, immediate tissue expander breast reconstruction from 2018 to 2023 was analyzed. Patients with AlloDerm and Cortiva (human ADM) were compared with those receiving Ovitex, and 90-day complications were analyzed by chi-squared and analysis of variance. Costs of each mesh were tabulated based on available market data.
Results:
Patient demographics were comparable. Of 127 patients, 85 received ovine ECM (163 breasts) and 42 received cadaveric ADM (81 breasts). No significant difference between the groups for complications requiring return to the operating room (12.7% ovine vs 14.8% human (P = 0.31) or minor complications (9.8% ovine vs 7.4% human, P = 0.34). There was no difference between reconstructive success and failure between the 2 groups (P = 0.066). The cost of Ovitex was 24%-38% cheaper than Cortiva and AlloDerm, respectively.
Conclusions:
In this longitudinal, single-surgeon study of 2 different types of meshes in 2-stage expander implant breast reconstruction, we found ovine multilaminated reinforced extracellular matrix (Ovitex) was comparable in outcomes with human acellular dermal matrices (AlloDerm and Cortiva). Ovine mesh was considerably cheaper. Multiple factors determine which mesh should be chosen for implant breast reconstruction. This study supports the use of Ovitex as a cost-effective substitute for human acellular dermal matrices in implant breast reconstruction.
